SOAT1 and parasitic infectious disease: Drugs targeting master JAK/STAT signaling can also be developed to treat parasitic infections or hypersensitivities, including allergic responses, which are either IgE-dominant (controlling STAT3α and STAT6) or IgG4-dominant (controlling STAT1α and STAT6) reactions.